The clinical rationale for menses-free contraception

Journal of Women's Health

Volumn 16, Issue 8, 2007, Pages 1171-1180

  Lin, Kat ^a,b   Barnhart, Kurt ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Penn Fertility Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHINYLESTRADIOL PLUS LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

ANEMIA; DISEASE ASSOCIATION; DYSMENORRHEA; HUMAN; MENORRHAGIA; MENSTRUAL CYCLE; MENSTRUATION; MENSTRUATION DISORDER; ORAL CONTRACEPTION; PELVIS PAIN SYNDROME; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

AMENORRHEA; CONTRACEPTIVES, ORAL, HORMONAL; DYSMENORRHEA; EVIDENCE-BASED MEDICINE; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MENORRHAGIA; MENSTRUAL CYCLE; MENSTRUATION; MENSTRUATION DISTURBANCES; PREMENSTRUAL SYNDROME; WOMEN'S HEALTH;

EID: 35348884398     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2007.0332     Document Type: Review

References (72)

1. Kaunitz AM. Menstruation: Choosing whether . . . and when. Contraception 2000;62:277.
2. American College of Obstetricians and Gynecologists. ACOG practice bulletin: Clinical management guidelines for obstetrician-gynecologists: Premenstrual syndrome. ACOG Pract Bull 2000;15:448.
3. Kjerulff KH, Erickson BA, Langenberg PW. Chronic gynecological conditions reported by U.S. women: Findings from the National Health Interview Survey, 1984 to 1992. Am J Public Health 1996;86:195.
4. Dawood MY. Dysmenorrhea. Clin Obstet Gynecol 1990;33:168.
5. Côté I, Jacobs P, Cumming D. Work loss associated with increased menstrual loss in the United States. Obstet Gynecol 2002;100:683.
6. French L. Dysmenorrhea. Am Fam Physician 2005;71:285.
7. Sundell G, Milsom I, Andersch B. Factors influencing the prevalence and severity of dysmenorrhoea in young women. Br J Obstet Gynaecol 1990;97:588.
8. Protheroe J. Modern management of menorrhagia. J Fam Plann Reprod Health Care 2004;30:118.
9. Fraser IS, McCarron G, Markham R. A preliminary study of factors influencing perception of menstrual blood loss volume. Am J Obstet Gynecol 1984;149:788.
10. Chimbira TH, Anderson AB, Turnbull A. Relation between measured menstrual blood loss and patient's subjective assessment of loss, duration of bleeding, number of sanitary towels used, uterine weight and endometrial surface area. Br J Obstet Gynaecol 1980;87:603.
11. The Merck manual of diagnosis and therapy, 17th ed. New York: John Wiley & Sons, 1999.
12. Westhoff C, Kaunitz AM. An overview of menstruation. Female Patient 2002;27(Suppl):4.
13. Krassas GE, Pontikides N, Kaltsas T, et al. Disturbances of menstruation in hypothyroidism. Clin Endocrinol (Oxf) 1999;50:655.
14. Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss - A population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966;45:320.
15. Spies JB. Uterine artery embolization for fibroids: Understanding the technical causes of failure. J Vasc Interv Radiol 2003;14:11.
16. Freeman EW. Premenstrual syndrome and premenstrual dysphoric disorder: Definitions and diagnosis. Psychoneuroendocrinology 2003;28(Suppl 3):25.
17. Halbreich U. The etiology, biology, and evolving pathology of premenstrual syndromes. Psychoneuroendocrinology 2003;28(Suppl 3):55.
18. Halbreich U, Borenstein J, Pearlstein T, Kahn LS. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 2003;28(Suppl 3):1.
19. Stout AL, Steege JF. Psychological assessment of women seeking treatment for premenstrual syndrome. J Psychosom Res 1985;29:621.
20. Steiner M. Premenstrual syndromes. Annu Rev Med 1997;48:447.
21. Pearlstein TB, Halbreich U, Batzar ED, et al. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry 2000;61:101.
22. Kraemer GR, Kraemer RR. Premenstrual syndrome: Diagnosis and treatment experiences. J Womens Health 1998;7:893.
23. Halbreich U, Bergeron R, Yonkers KA, Freeman E, Stout AL, Cohen L. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 2002;100:1219.
24. Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA 1997;278:983.
25. Cohen LS, Soares CN, Yonkers KA, Bellew KM, Bridges IM, Steiner M. Paroxetine controlled release for premenstrual dysphoric disorder: A double-blind, placebo-controlled trial. Psychosom Med 2004;66:707.
26. Steiner M, Hirschberg AL, Bergeron R, Holland F, Gee MD, Van Erp E. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. Am J Obstet Gynecol 2005;193:352.
27. Pearlstein TB, Bellew KM, Endicott J, Steiner M. Paroxetine controlled release for premenstrual dysphoric disorder: Remission analysis following a randomized, double-blind, placebo-controlled trial. Prim Care Companion J Clin Psychiatry 2005;7:53.
28. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl J Med 1995;332:1529.
29. Miner C, Brown E, McCray S, Gonzales J, Wohlreich M. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: A randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2002;24:417.
30. Steiner M, Brown E, Trzepacz P, et al. Fluoxetine improves functional work capacity in women with premenstrual dysphoric disorder. Arch Women Ment Health 2003;6:71.
31. Johannes CB, Crawford SL. Menstrual bleeding, hormones, and the menopausal transition. Semin Reprod Endocrinol 1999;17:299.
32. Svalheim S, Tauboll E, Bjornenak T, et al. Do women with epilepsy have increased frequency of menstrual disturbances? Seizure 2003;12:529.
33. Herzog AG. Reproductive endocrine considerations and hormonal therapy for women with epilepsy. Epilepsia 1991;32(Suppl 6):S27.
34. Carter JE. Combined hysteroscopic and laparoscopic findings in patients with chronic pelvic pain. J Am Assoc Gynecol Laparosc 1994;2:43.
35. Demco L. Mapping the source and character of pain due to endometriosis by patient-assisted laparoscopy. J Am Assoc Gynecol Laparosc 1998;5:241.
36. Silberstein S, Merriam G. Sex hormones and headache 1999 (menstrual migraine). Neurology 1999;53(Suppl 1):S3.
37. Silberstein SD. Menstrual migraine. J Womens Health Gend Based Med 1999;8:919.
38. Silberstein SD, Merriam GR. Sex hormones and headache. J Pain Symptom Manage 1993;8:98.
39. MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology 2004;63:351.
40. Martin VT. Menstrual migraine: A review of prophylactic therapies. Curr Pain Headache Rep 2004;8:229.
41. American College of Obstetricians and Gynecologists. ACOG practice bulletin: The use of hormonal contraception in women with coexisting medical conditions. Int J Gynaecol Obstet 2001;75:93.
42. Bhatia SC, Bhatia SK. Diagnosis and treatment of premenstrual dysphoric disorder. Am Fam Physician 2002;66:1239.
43. Vrieze A, Postma DS, Kerstjens HA. Perimenstrual asthma: A syndrome without known cause or cure. J Allergy Clin Immunol 2003;112:271.
44. Loudon NB, Foxwell M, Potts DM, Guild AL, Short RV. Acceptability of an oral contraceptive that reduces the frequency of menstruation: The tri-cycle pill regimen. Br Med J 1977;2:487.
45. Gladwell M. John Rock's error. New Yorker 3/13/2000;76:52.
46. Eaton SB, Pike MC, Short RV, et al. Women's reproductive cancers in evolutionary context. Q Rev Biol 1994;69:353.
47. Dayal M, Barnhart KT. Noncontraceptive benefits and therapeutic uses of the oral contraceptive pill. Semin Reprod Med 2001;19:295.
48. Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000;95:261.
49. Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 2002;186:1142.
50. Vercellini P, Frontino G, De Giorgi O, Pietropaolo G, Pasin R, Crosignani PG. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril 2003;80:560.
51. Davis AJ. Advances in contraception. Obstet Gynecol Clin North Am 2000;27:597.
52. Kaunitz AM. Oral contraceptive use in perimenopause. Am J Obstet Gynecol 2001;185(Suppl 2):S32.
53. Cooper C, Hannaford P, Croft P, Kay CR. Oral contraceptive pill use and fractures in women: A prospective study. Bone 1993;14:41.
54. Vessey M, Mant J, Painter R. Oral contraception and other factors in relation to hospital referral for fracture. Findings in a large cohort study. Contraception 1998;57:231.
55. Michaelsson K, Baron JA, Farahmand BY, Persson I, Ljunghall S. Oral contraceptive use and risk of hip fracture: A case-control study. Lancet 1999;353:1481.
56. Kadir RA, Sabin CA, Pollard D, Lee CA, Economides DL. Quality of life during menstruation in patients with inherited bleeding disorders. Haemophilia 1998;4:836.
57. Schneider MB, Fisher M, Friedman SB, Bijur PE, Toffler AP. Menstrual and premenstrual issues in female military cadets: A unique population with significant concerns. J Pediatr Adolesc Gynecol 1999;12:195.
58. Bennell K, White S, Crossley K. The oral contraceptive pill: A revolution for sportswomen? Br J Sports Med 1999;33:231.
59. Frankovich RJ, Lebrun CM. Menstrual cycle, contraception, and performance. Clin Sports Med 2000;19:251.
60. Sulak PJ, Cressman BE, Waldrop E, Holleman S, Kuehl TJ. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol 1997;89:179.
61. den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception 1999;59:357.
62. Sulak PJ, Carl J, Gopalakrishnan I, Coffee A, Kuehl TJ. Outcomes of extended oral contraceptive regimens with a shortened hormone-free interval to manage breakthrough bleeding. Contraception 2004;70:281.
63. Anderson FD, Hait H, the Seasonale-301 Study Group. A multicenter, randomized study of an extended-cycle oral contraceptive. Contraception 2003;68:89.
64. Anderson FD, Hait H, Hsiu J, Thompson-Graves AL, Wilborn WH, Williams RF. Endometrial microstructure after long-term use of a 91-day extended-cycle oral contraceptive regimen. Contraception 2005;71:55.
65. Anderson FD, Gibbons W, Portman D. Long-term safety of an extended-cycle oral contraceptive (Seasonale): A 2-year multicenter open-label extension trial. Am J Obstet Gynecol 2006;195:92.
66. Anderson FD, Gibbons W, Portman D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception 2006;73(3):229.
67. Machado RB, Fabrini P, Cruz AM, Maia E, da Cunha Bastos A. Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 microg) and gestodene (75 microg). Contraception 2004;70:365.
68. Kwiecien M, Edelman A, Nichols MD, Jensen JT. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: A randomized trial. Contraception 2003;67:9.
69. Lambert J, Newton W. Continuous use of oral contraceptives reduces bleeding. J Fam Pract 2003;52:601.
70. Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: A randomized trial. Obstet Gynecol 2003;101:653.
71. Archer DF, Jensen JT, Johnson JV, Borisute H, Grubb GS, Constantine GD. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: Phase 3 study results. Contraception 2006;74:439.
72. Sulak, PJ, Kuehl TJ, Coffee A, Willis S. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen. Am J Obstet Gynecol 2006;195:935.